Why Galectin Therapeutics (GALT) Stock Is Plummeting Today

NEW YORK (TheStreet) -- Galectin Therapeutics  (GALT) plummeted Tuesday after the company reported poor results in an early-stage trial of its experimental drug for treatment of a fatty liver disease.

The drug, GR-MD-02, showed no difference from a placebo in nearly all measures to treat nonalcoholic steatohepatitis, or NASH. Galectin derived the drug from fruit pectin.

For more on this story, read TheStreet's Adam Feuerstein's article here.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 55.91% to $6.41 at 1 p.m. More than 4.4 million shares had changed hands, compared to the average volume of 298,559.

GALT ChartGALT data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Galectin Therapeutics (GALT) Stock Drops on Drug Failure, Downgraded

Galectin Therapeutics (GALT) Stock Declines on Drug Failure, Rating Cut

5 Stocks Under $10 That Could Make You a Lot of Money

These Biotech Names Are on My Radar

Top Swing Trade Ideas for Monday: Cerus, Endocyte, More